Extrachromosomal microDNA Signature as a Candidate Biomarker in Pediatric Acute Lymphoblastic Leukemia

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, with relapsed and refractory cases leading to significant mortality.
• Current monitoring methods for ALL lack accessible, minimally invasive biomarkers for frequent disease surveillance.
• MicroDNAs, novel extrachromosomal DNA, originate from highly active or accessible gene regions.

Purpose of the Study:

• To investigate changes in the microDNA-producing gene repertoire during different stages of pediatric ALL.
• To identify potential microDNA-based biomarkers for disease monitoring and prognosis in pediatric ALL.

Main Methods:

• Characterization of microDNAs in paired bone marrow and plasma samples from 52 pediatric ALL patients at diagnosis, relapse, and remission.
• Comparative analysis of microDNA profiles to identify disease-specific gene signatures.
• Validation of candidate biomarkers in plasma samples.

Main Results:

• A distinct panel of 289 microDNA-producing genes was identified in patients with active disease (diagnosis and relapse) but not in remission.
• Eleven microDNA-producing genes, found in plasma, were significantly associated with diagnosis and relapse, and overrepresented in patients who later relapsed.
• Signature genes are known to be involved in cancer proliferation and drug response.

Conclusions:

• MicroDNAs represent a potential new class of biomarkers for acute lymphoblastic leukemia (ALL).
• Plasma-derived microDNA signatures offer a minimally invasive approach for precision diagnostics and disease monitoring in pediatric ALL.
• Further validation in independent cohorts is necessary to confirm the clinical utility of these microDNA biomarkers.